Real-world experience of serial serum levels of GS-331007 in chronic hepatitis C hemodialysis patients during and after sofosbuvir/velpatasvir therapy

Abstract

Real world experience of serial serum levels of GS-331007 in chronic hepatitis C hemodialysis patients during and after sofosbuvir/ velpatasvir therapy,

Sofosbuvir plus velpatasvir combination for the treatment of chronic hepatitis C in patients with end stage renal disease on renal replacement therapy: A systematic review and meta‐analysis

“…[4][5][6][7] Indeed, recent data shows that although GS-331007 levels are several times higher in patients on RRT, their levels do not accumulate during the course of treatment and disappears by 4-weeks of treatment completion. 8 The combination of SOF with velpatasvir (VEL), an NS5A inhibitor, is an effective and safe pan-genotypic regimen that is recommended as a first-line therapy for patients with chronic Hepatitis C (CHC) according to various society guidelines. [9][10][11] However, literature on the use of the combination of SOF and VEL in patients with ESRD on RRT is scanty.…”

Bouncing back or slowing down renal function decline after hepatitis C virus eradication

“…Among ESRD patients, GS-331007 was smoothly removed by regular hemodialysis, which was never detected throughout 1 month to 1 year after the end of sofosbuvir/velpatasivir treatment. 3 The authors did not show the overall eGFR change after directly acting antivirals (DAAs) therapy. Rather, they observed an improvement of eGFR in patients with baseline eGFR ≤60 mL/min/1.73 m 2 but a decreased eGFR in patients with baseline eGFR >60 mL/min/1.73 m 2 .…”

“…We now clearly know that its use is very safe in patients whose eGFR was less than 30 mL/min/1.73 m 2 after the approval of the FDA in 2019. Among ESRD patients, GS‐331007 was smoothly removed by regular hemodialysis, which was never detected throughout 1 month to 1 year after the end of sofosbuvir/velpatasivir treatment 3 …”